Edition:
United States

Zimmer Biomet Holdings Inc (ZBH.N)

ZBH.N on New York Stock Exchange

112.38USD
11:12am EDT
Change (% chg)

$0.64 (+0.57%)
Prev Close
$111.74
Open
$111.69
Day's High
$112.96
Day's Low
$111.69
Volume
20,196
Avg. Vol
299,783
52-wk High
$133.45
52-wk Low
$104.28

Select another date:

Tue, May 22 2018

BRIEF-Zimmer Biomet Holdings Announces 510(K) Clearance For Zyston Strut Open Titanium Interbody Spacer System

* ZIMMER BIOMET HOLDINGS ANNOUNCES 510(K) CLEARANCE FOR ZYSTON STRUT OPEN TITANIUM INTERBODY SPACER SYSTEM Source text for Eikon: Further company coverage:

BRIEF-Zimmer Biomet Reports Q1 Earnings Per Share $0.85

* ZIMMER BIOMET ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Zimmer Biomet Announces FDA Clearance And First Surgical Case Of The Persona Trabecular Metal Tibia

* ZIMMER BIOMET ANNOUNCES FDA CLEARANCE AND FIRST SURGICAL CASE OF THE PERSONA® TRABECULAR METAL™ TIBIA

BRIEF-Zimmer Biomet Says CEO Hanson's FY'17 Total Compensation Was $16.3 Mln

* ZIMMER BIOMET SAYS CEO BRYAN HANSON'S FY 2017 TOTAL COMPENSATION WAS $16.3 MLN - SEC FILING

Zimmer beats knee implant bellwether case on appeal

A Pepsi bottling plant worker has lost his bid to revive a lawsuit claiming Zimmer Biomet Holdings Inc failed to warn that its NexGen knee implants were prone to premature loosening in patients who engage in activities that need knee flexibility.

BRIEF-Zimmer Biomet Holdings Files For Offering Of Floating Rate Notes Due 2021

* ZIMMER BIOMET HOLDINGS INC - FILES FOR OFFERING OF FLOATING RATE NOTES DUE 2021 AND NOTES DUE 2023 - SEC FILING Source text: (http://bit.ly/2tzlxYD) Further company coverage:

BRIEF-Zimmer Biomet Holdings Reports Q4 EPS Of $6.16

* ZIMMER BIOMET ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 RESULTS

BRIEF-Zimmer Biomet Holdings Announces FDA Clearance Of Sidus Stem-Free Shoulder System

* ZIMMER BIOMET HOLDINGS SAYS THE SIDUS SYSTEM WILL BE AVAILABLE IN U.S BEGINNING IN Q1 OF 2018 Source text for Eikon: Further company coverage:

BRIEF-Zimmer Biomet Says Positive Results From Progress II Trial Of Autologous Protein Solution Prepared With nSTRIDE Aps Kit In Treating Osteoarthritis

* ZIMMER BIOMET HOLDINGS- POSITIVE RESULTS FROM PROGRESS II TRIAL OF AUTOLOGOUS PROTEIN SOLUTION PREPARED WITH NSTRIDE APS KIT IN TREATING OSTEOARTHRITIS Source text for Eikon: Further company coverage:

BRIEF-Zimmer Biomet Names Bryan Hanson CEO

* ZIMMER BIOMET ANNOUNCES APPOINTMENT OF BRYAN C. HANSON AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

Select another date: